Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Miguel A. Molina"'
Autor:
Rosario García-Campelo, Noemí Reguart, Oscar Arrieta, Ana Giménez-Capitán, Niki Karachaliou, Ana Drozdowskyj, Rafael Rosell, Imane Chaib, Miguel Angel Molina-Vila, Erika Aldeguer, Jing-Hua Chen
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100113-(2021)
JTO Clinical and Research Reports
JTO Clinical and Research Reports
Introduction DNA repair capacity, as exemplified by BRCA1 gene expression, is related with outcome to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant NSCLC. Olaparib, a PARP inhibitor, reduces BRCA1 expression. Olaparib was tested in com
Autor:
Carlos Pedraz-Valdunciel, PhD, Masaoki Ito, MD, Stavros Giannoukakos, PhD student, Ana Giménez-Capitán, MSc, Miguel Ángel Molina-Vila, PhD, Rafael Rosell, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100604- (2023)
Introduction: As recently evidenced by the ADAURA trial, most patients with stages IB to IIIA of resected EGFR-mutant lung adenocarcinoma benefit from osimertinib as adjuvant therapy. Nevertheless, predictive markers of response and recurrence are st
Externí odkaz:
https://doaj.org/article/d9bf3f77370d44da9f2f5fc06d7d9205
Autor:
Niki Karachaliou, MD, PhD, Oscar Arrieta, MD, Ana Giménez-Capitán, BSc, Erika Aldeguer, BSc, Ana Drozdowskyj, PhD, Imane Chaib, PhD, Noemí Reguart, MD, PhD, Rosario Garcia-Campelo, MD, Jing-Hua Chen, MD, Miguel Angel Molina-Vila, PhD, Rafael Rosell, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100113- (2021)
Introduction: DNA repair capacity, as exemplified by BRCA1 gene expression, is related with outcome to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant NSCLC. Olaparib, a PARP inhibitor, reduces BRCA1 expression. Olaparib was tested in co
Externí odkaz:
https://doaj.org/article/08a2152e29af4e089606394482732718
Autor:
Masaoki Ito, MD, Jordi Codony-Servat, PhD, Ana Giménez-Capitán, BSc, Mireia Serra-Mitjans, MD, Francisco Pérez-Ochoa, MD, David Llige, BSc, Imane Chaib, PhD, Ramón Rami-Porta, MD, Carme Obiols, MD, Sergi Call, MD, Manuela Iglesias, MD, José Belda-Sanchis, MD, Xavier Tarroch-Sarasa, MD, Niki Karachaliou, MD, Miguel Angel Molina-Vila, PhD, Morihito Okada, MD, Rafael Rosell, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 4, Pp 100084- (2020)
Introduction: EGFR mutation-positive lung adenocarcinoma (LUAD) displays impaired phosphorylation of ERK and Src-homology 2 domain-containing phosphatase 2 (SHP2) in comparison with EGFR wild-type LUADs. We hypothesize that SHP2 expression could be p
Externí odkaz:
https://doaj.org/article/ba1595860e4f4a8a8b44fa1c6caeb13a